



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY

Serum microRNA-122 Levels in Egyptian Patients with Chronic Hepatitis C virus Genotype 4 Infection before and after treatment with Direct Acting Antiviral Drugs

Thesis

Submitted for Partial Fulfillment of MD Degree in Internal Medicine

By

Sameh Mostafa Elwakeel

MSc Internal Medicine Ain Shams University

Under Supervision of

Prof. Dr. Essam Mohammad Bayoumy Helal

Professor of Internal Medicine

Faculty of Medicine- Ain Shams University

Prof. Dr. Moataz Mohammad Sayed

Professor of Internal Medicine

Faculty of Medicine- Ain Shams University

Dr. Tari Magdy Aziz George

Lecturer of Internal Medicine

Faculty of Medicine- Ain Shams University

Dr. Christina Alfons Anwar

Lecturer of Internal Medicine

Faculty of Medicine - Ain Shams University

Dr. Sara Hassan Agwa

Assistant Consultant of Clinical Pathology & Molecular Biology

Faculty of Medicine - Ain Shams University

**Faculty of Medicine
Ain Shams University**

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسببائك لا علم لنا
إلا ما علمتنا إنك أنت
العليم الكبير

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgement

First of all my prayerful gratitude should be submitted to the merciful Allah, whose help me always seek and without his willing I will achieve nothing.

*Then, I would like to express my profound and greatest gratitude to **Prof. Dr. Essam Mohammad Bayoumy Helal**, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for his guidance, beneficial remarks constructive and meticulous supervision. It has been a great honor and extreme pleasure for me to proceed with this work under his kind supervision. I readily owe the success of this work to his help and support.*

*I would like also to express my deep thanks and sincere gratitude to **Prof. Dr. Moataz Mohammad Sayed**, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for his constructive guidance, beneficial remarks continuous support, direction and meticulous revision of this work.*

*I would like to express my sincere appreciation to **Dr. Tari Magdy Aziz George**, Lecturer of Internal Medicine, Faculty of Medicine, Ain Shams University, for her kind help, sincere encouragement that made the accomplishment of this work possible.*

*I would like to express my sincere appreciation to **Dr. Christina Alfons Anwar**, Lecturer of Internal Medicine, Faculty of Medicine, Ain Shams University, for her kind help that made the accomplishment of this work possible.*

*I really grateful to **Dr. Sara Hassan Agwa**, Assistant Consultant of Clinical Pathology & Molecular Biology, Faculty of Medicine, Ain Shams University, for continuous encouragement and moral support. Lastly, I don't forget **my family, my wife and my sons** for their full support, prayers and wishes were a great motive to accomplish this work and thanks to my friends and my patients for their honest cooperation.*

Contents

Subject	Page No.
List of Abbreviations	I
List of Tables	VII
List of Figures	IX
Introduction and Aim of the Study	1
Review of Literature	
Chapter One: Hepatitis C Virus.....	7
Chapter Two: Hepatocellular carcinoma	45
Chapter Three: MicroRNAs.....	89
Chapter Four: HCC development after HCV infection treatment: possible role of MicroRNA-122.....	119
Patients and Methods.....	129
Results	138
Discussion	161
Summary	176
Conclusion.....	181
Recommendations.....	182
References.....	183
Arabic Summary	\

List of Abbreviations

Abb.	Full term
4-HNE	Trans-4-hydroxy-2-nonenal.
A1ATD	Alpha 1 Antitrypsin Deficiency.
AASLD	American Associated Society of liver disease
AFP	Alpha fetoprotein.
GPC3	Glypican-3
AFU	Alpha-l-fucosidase
AGO2	Argonuate 2
AIH	Autoimmune hepatitis
AJCC	American Joint Committee on Cancer
ALD	Alcoholic liver disease
ALP	Alkaline phosphatase
ALT	Alanineaminotransferase
ANA	Antinuclear antibody
ASR	Analyte-specefic reagent
AST	Aspartate aminotransferase
AUC	Area under curve
BCLC	Barcelona Clinic Liver Cancer
BHLC	Basic helix–loop–helix protein
BMI	Body mass index.
CBC	Complete blood count
CDK6	Cyclin-dependent kinase 6
CDKN1A	Cyclin-dependent kinase inhibitor 1A
CLIP	The Cancer of the Liver Italian Program
CREB1	cAMP responsive element binding protein 1
CT	Computed tomography

Abb.	Full term
CTP	Child-Turcotte-Pugh
CTLA-4	Cytotoxic T lymphocyte antigen 4
DAAS	Direct acting antiviral drugs
DCP	Des-gamma carboxy prothrombin
DHS	Demographic Health Survey
DILI	Drug-induced liver injury
DM	Diabetes mellitus.
DNA	Deoxyribonucleic acid.
DUS	Doppler us.
EASL	European Association for the study of Liver Disease
ECG	Electrocardiogram
ECM	Extracellular matrix
EDHS	Egypt Demographic and Health Surveys.
EGFR	The epidermal growth factor receptor
EHM	Extrahepatic manifestations
ELISA	Enzyme- linked immunosorbent assay.
ESLC	Egyptian Society of Liver Cancer
EUS	Endoscopic US
FDA	Food and drug administration
FGF	Fibroblast growth factor
Fib-4	Fibrosis -4
FN1	Fibronectin 1
GEP	Granulin-epithelin precursor
GGT	Gamma-glutamyl transferase
GGT mRNA	Gamma-glutamyl transferase mRNA

Abb.	Full term
GWAS	Genome-wide association studies
Hb	Haemoglobin
HBeAg	Hepatitis B e antigen
HBsAg	Hepatitis B surface antigen
HBV	Hepatitis B Virus
HBXIP	Hepatitis B virus X interacting protein
HCC	Hepatocellular carcinoma
HCV	Hepatitis c virus
HDV	Hepatitis D virus
HFL	Hepatic focal lesion
HGF/SF	Hepatocyte growth factor/scatter factor
HIV	Human immune deficiency virus
HSCS	Hepatic stellate cells
HTERT mRNA	Human telomerase reverse transcriptase mRNA
IDU	Intravenous drug users
IGF-1R	Insulin-like growth factor 1 receptor
IGF-II	Insulin-like growth factor-II
INR	International normalization ratio
IRB	Institutional Review Board
IRF1	Interferon regulatory factor 1
ISGS	Interferon stimulated gene
LC	Liver cancer
MMP2	Matrix metalloproteinase
MDCT	Multi-detector CT.
MELD	Model for end-stage liver disease

Abb.	Full term
miR-122	MicroRNA-122
MRI	Magnetic resonance imaging.
mRNA	Messenger ribonucleic acid
MAIT	Mucosal associated invariant cell
NAFLD	Non alcoholic fatty liver disease
NASH	Non alcoholic steatohepatitis
NCCVH	National committee of control of viral Hepatitis
NK	Natural killer
NF-κB	Nuclear factor κ B
Non-CHN	Non characteristic hepatic nodul
NNPI	Non-nucleoside polymerase inhibitor
NNPIs	Non- nucleoside polymerase inhibitors
NPIs	Nucleoside polymerase inhibitors
NS	Non structural
NS3/4A	Nonstructural proteins 3/4A
NS5A	Nonstructural protein 5A.
NS5B	Nonstructural protein 5B
PAK4	p21-activated kinase 4
PAT	Parenteral antischistosomiasis campaigns
PBC	Primary biliary cirrhosis
PCR	Polymerase chain reaction
PD1	Programmed death
PIs	Protease inhibitors
PTTG	Pituitary tumour transforming gene
PBF	Pituitary binding factor

Abb.	Full term
PLT	Platelets
PPARα	Peroxisome proliferator-activated receptor α
PS	Performance status
PVT	Portal vein thrombosis
RFA	Radiofrecuencablation
RISC	RNA-induced silencing complex
RNA	Ribonucleic acid.
ROS	Reactive oxygen species
RQ	Relative quantification
RT-PCR	Reverse transcription polymerase chain reaction
SCD	Stearoyl-CoA desaturase
SIRT1	Sirtuin 1
snoRNAs	Small nucleolar RNAs
SNPs	Single nucleotide polymorphisms
Sp1	specificity protein 1
STAT3	Signal transducer and activator of transcription 3
SVR	Sustained virologic response
TACE	Trans arterial chemoembolization
TGF-Beta1	Transforming Growth Factor-Beta1
TLC	Total leucocytic count
TLR	Toll-like receptor
TNF-α	Tumour necrosis factor
tRNA	Transfer RNA
TSGF	Tumor-Specific Growth Factor

Abb.	Full term
US	Ultrasound
USA	Unites States of America
UTR	Untranslated region
VEGF	Vascular endothelial growth factor
WHO	World Health Organization

List of Tables

<i>Table</i>	<i>Title</i>	<i>Page</i>
Table 1	DAAAs Approved in Europe 2018	35
Table 2	Performance status score	77
Table 3	American Joint Committee on Cancer staging system for Hepatocellular carcinoma.	78
Table 4	BCLC staging for HCC	79
Table 5	Okuda system for HCC staging	80
Table 6	The Cancer of the Liver Italian Program score	81
Table 7	CBC distribution between studied groups	140
Table 8	Comparison between the studied groups as regard liver enzymes and alphafetoprotein	143
Table 9	Comparison between the studied groups as regard other laboratory data	146
Table 10	Comparison between the studied groups as regard Fib-4 & child score	149
Table 11	Comparison between the studied groups as regard microRNA- 122	152

<i>Table</i>	<i>Title</i>	<i>Page</i>
Table 12	Comparison between groups A &B and HCV group x as regard microRNA -122 level	155
Table 13	Correlations between microRNA122 change and other variables in groups C&D	158
Table 14	Correlations between baseline microRNA-122 level and other variables in groups B	159
Table 15	ROC Curve for microRNA-122 as regard cutoff value of HCC	160
